RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM-Reference-Cited by-同舟云学术

RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM

Published:1988-08 Issue:8606 Volume:332 Page:293-298
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Goldhaber SamuelZ.,Heit John,Sharma G.V.R.K.,Nagel J.Stevan,Kim Ducksoo,Parker J.Anthony,Drum David,Reagan Kathleen,Anderson James,Kessler CraigM.,Markis John,Dawley Douglas,Meyerovitz Michael,Vaughan DouglasE.,Tumeh SabahS.,Loscalzo Joseph,Selwyn AndrewP.,Braunwald Eugene

Publisher

Elsevier BV

Subject

General Medicine

Reference16 articles.

1. Acute pulmonary embolism treated with tissue plasminogen activator;Goldhaber;Lancet,1986

2. Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator;Goldhaber;Sem Thromb Hemostas,1987

3. Thrombolytic therapy of acute pulmonary embolism: Current status and future potential;Goldhaber;J Am Coll Cardiol,1987

4. Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator;Come;JACC,1987

5. Pulmonary perfusion after rt-PA therapy for acute embolism: Early improvement assessed with segmental perfusion scanning;Parker;Radiology,1988

Cited by 280 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing the management of acute intermediate-high-risk pulmonary embolism: The enduring legacy of Professor Guy Meyer;La Presse Médicale;2024-09

2. Acute Pulmonary Embolism: Evidence, Innovation, and Horizons;Current Cardiology Reports;2024-08-31

3. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications;Seminars in Thrombosis and Hemostasis;2024-03-01

4. Safety and Efficacy of Reduced-Dose Versus Full-Dose Alteplase for Acute Pulmonary Embolism: A Multicenter Observational Comparative Effectiveness Study*;Critical Care Medicine;2024-01-03

5. A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity;Pharmaceuticals;2023-11-02